[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
February 10, 1997

NSAID Gastropathy-Reply

Author Affiliations

Phoenix, Ariz

Arch Intern Med. 1997;157(3):364. doi:10.1001/archinte.1997.00440240130027
Abstract

True, nabumetone alone has the body of significant gastrosparing data to corroborate its safety advantages to date. Other "new NSAIDs" claim "tolerance" (not always the same as safety); however, as we indicated, "there are limited available data to rank individual NSAID GI tract tolerability accurately...."1 But what was "new" becomes "old" as COX-II (a mitogen-inducible form of prostaglandin cyclooxygenase) NSAIDs loom on the horizon—awaiting data to corroborate their safety advantages. In the meantime, it is especially important to consider alternatives to NSAIDS, such as analgesic and topical agents and sensible pain management programs, for individuals who are at higher risk for the complications of gastropathy.

First Page Preview View Large
First page PDF preview
First page PDF preview
×